<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
pmid: 6828303
The increased use of chemotherapeutic agents has resulted in longer patient survival; consequently, the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Many of these drugs cause aggravating ocular irritation (fluorouracil, methotrexate), canalicular fibrosis with epiphora (fluorouracil), retinopathy (mitotane, tamoxifen), corneal opacities (tamoxifen), cataracts (busulfan, methotrexate), and optic or ocular motor abnormalities (carmustine, vinblastine, vincristine). Based on the data in the National Registry of Drug-Induced Ocular Side Effects and the literature, adverse ocular reactions of the more commonly used chemotherapeutic agents are reviewed.
Adult, Eye Diseases, Neoplasms, Animals, Humans, Antineoplastic Agents, Child
Adult, Eye Diseases, Neoplasms, Animals, Humans, Antineoplastic Agents, Child
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 123 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |